Seres Therapeutics Inc Stock Price, News & Analysis

Seres Therapeutics (Nasdaq: MCRB) announced new findings from its SER-109 Phase 3 ECOSPOR III clinical study related to recurrent C. difficile infection. The study demonstrated rapid engraftment of SER-109-derived bacteria in the gastrointestinal tract, achieving significant metabolic changes that create an unfavorable environment for C. difficile growth. The data revealed an 88.9% sustained clinical response rate at eight weeks post-treatment, with no serious adverse events reported. SER-109 has received FDA Breakthrough Therapy and Orphan Drug designations.

Seres Therapeutics (Nasdaq: MCRB) announced promising results from its Phase 1b trial of SER-287 for treating active mild-to-moderate ulcerative colitis (UC). The study demonstrated a 40% clinical remission rate in patients receiving daily SER-287 compared to 0% in the placebo group. Data highlighted SER-287's safety and favorable tolerability profile, with no serious adverse events noted. The ongoing Phase 2b ECO-RESET study continues to enroll patients, aiming to provide topline results in late 2021. FDA Fast Track designation for SER-287 reinforces its potential as a transformative therapy for UC.

Seres Therapeutics (Nasdaq: MCRB) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14 at 11:40 a.m. ET. A live audio webcast will be accessible in the ‘Investors and Media’ section of their website, with a replay available an hour post-event for 21 days.

Seres is focused on microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for C. difficile infection and receiving FDA Breakthrough Therapy status. Other programs include SER-287 for ulcerative colitis and SER-401 for metastatic melanoma.

Seres Therapeutics (Nasdaq: MCRB) has announced participation in two virtual investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will take place on December 1, 2020, featuring management in 1x1 meetings and a fireside chat available from November 23, 2020. The 3rd Annual Evercore ISI HealthCONx Virtual Conference is scheduled for December 2, 2020, also including management 1x1 meetings. Seres is a leader in microbiome therapeutics with advanced programs for recurrent C. difficile infection and ulcerative colitis.

Seres Therapeutics (MCRB) reported a net loss of $30.3 million for Q3 2020, up from $16.4 million in Q3 2019, primarily due to clinical and development expenses. The company announced that SER-109, its lead microbiome therapy, showed a 30.2% absolute reduction in recurrent C. difficile infections in its Phase 3 study, supporting its potential FDA approval. Following a successful capital raise, Seres has $320.3 million in cash, enhancing its growth prospects. Additionally, SER-287 and SER-301 are in clinical trials, advancing the company’s broad microbiome pipeline.

Seres Therapeutics (Nasdaq: MCRB) has initiated the dosing of participants in its Phase 1b trial for SER-301, aimed at treating active mild-to-moderate ulcerative colitis (UC). SER-301 is a microbiome therapeutic designed to counteract gastrointestinal inflammation and is based on insights from the earlier SER-287 trial. The study in Australia and New Zealand will involve 65 patients, focusing on safety and pharmacokinetics. Seres will receive a $10 million milestone payment from Nestlé Health Science upon trial initiation.

Seres Therapeutics (Nasdaq: MCRB) announced a conference call on November 9, 2020, at 8:30 a.m. ET to discuss Q3 2020 results and provide a business update. The SER-109 program has achieved significant clinical milestones, including Breakthrough Therapy and Orphan Drug designations from the FDA, targeting recurrent C. difficile infections. Additional programs like SER-287 and SER-401 are in various stages of clinical evaluation, with FDA designations indicating potential for innovation in microbiome therapeutics.

Seres Therapeutics (Nasdaq: MCRB) has expanded its leadership team by appointing David S. Ege as Executive Vice President and Chief Technology Officer, and Jayne M. Gansler as Executive Vice President and Chief People Officer. These appointments coincide with positive Phase 3 results for SER-109, which aims to be the first FDA-approved microbiome therapy. Previous leadership additions include Lisa von Moltke as Chief Medical Officer and Terri Young as Chief Commercial and Strategy Officer. The company is preparing for commercialization and enhancing its capabilities to support growth in the microbiome therapeutics space.

Seres Therapeutics (Nasdaq: MCRB) has announced positive Phase 3 results from the ECOSPOR III trial of SER-109, presented at the Virtual ACG Annual Meeting. The trial demonstrated a statistically significant reduction in C. difficile infection recurrence at 12 weeks post-treatment, with a 31.1% absolute risk reduction compared to placebo. The study included 182 patients and confirmed the therapy's efficacy across age groups. SER-109 aims to transform treatment for recurrent C. difficile infection, having received FDA Breakthrough Therapy and Orphan Drug designations.